These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

576 related articles for article (PubMed ID: 23456027)

  • 1. Vascular calcification: an update on mechanisms and challenges in treatment.
    Wu M; Rementer C; Giachelli CM
    Calcif Tissue Int; 2013 Oct; 93(4):365-73. PubMed ID: 23456027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of NFATc1 in the Bone-Vascular Axis Calcification Paradox.
    Gu W; Wang Z; Sun Z; Bao Z; Zhang L; Geng Y; Jing L; Mao X; Li L
    J Cardiovasc Pharmacol; 2020 Mar; 75(3):200-207. PubMed ID: 31868826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin.
    Collin-Osdoby P
    Circ Res; 2004 Nov; 95(11):1046-57. PubMed ID: 15564564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease.
    D'Amelio P; Isaia G; Isaia GC
    J Endocrinol Invest; 2009; 32(4 Suppl):6-9. PubMed ID: 19724159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular calcification in type-2 diabetes and cardiovascular disease: Integrative roles for OPG, RANKL and TRAIL.
    Harper E; Forde H; Davenport C; Rochfort KD; Smith D; Cummins PM
    Vascul Pharmacol; 2016 Jul; 82():30-40. PubMed ID: 26924459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of receptor activator of NF-kappaB ligand by denosumab attenuates vascular calcium deposition in mice.
    Helas S; Goettsch C; Schoppet M; Zeitz U; Hempel U; Morawietz H; Kostenuik PJ; Erben RG; Hofbauer LC
    Am J Pathol; 2009 Aug; 175(2):473-8. PubMed ID: 19590040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The receptor activator of nuclear factor κΒ ligand receptor leucine-rich repeat-containing G-protein-coupled receptor 4 contributes to parathyroid hormone-induced vascular calcification.
    Carrillo-López N; Martínez-Arias L; Alonso-Montes C; Martín-Carro B; Martín-Vírgala J; Ruiz-Ortega M; Fernández-Martín JL; Dusso AS; Rodriguez-García M; Naves-Díaz M; Cannata-Andía JB; Panizo S
    Nephrol Dial Transplant; 2021 Mar; 36(4):618-631. PubMed ID: 33367746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent highlights of ATVB: calcification.
    Virmani R; Joner M; Sakakura K
    Arterioscler Thromb Vasc Biol; 2014 Jul; 34(7):1329-32. PubMed ID: 24876349
    [No Abstract]   [Full Text] [Related]  

  • 9. RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway.
    Panizo S; Cardus A; Encinas M; Parisi E; Valcheva P; López-Ongil S; Coll B; Fernandez E; Valdivielso JM
    Circ Res; 2009 May; 104(9):1041-8. PubMed ID: 19325147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Expression of osteoprotegerin and soluble ligand of receptor of kappa-B transcription factor activator in the calcification of aortic valve].
    Voronkina IV; Irtyuga OB; Smagina LV; Adamova PE; Zhiduleva EV; Malashicheva AB; Sibagatullina YS; Kruk LP; Gordeev ML; Moiseeva OM
    Biomed Khim; 2019 Jan; 65(1):57-62. PubMed ID: 30816098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteoprotegerin, vascular calcification and atherosclerosis.
    Van Campenhout A; Golledge J
    Atherosclerosis; 2009 Jun; 204(2):321-9. PubMed ID: 19007931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-talk of receptor activator of nuclear factor-κB ligand signaling with renin-angiotensin system in vascular calcification.
    Osako MK; Nakagami H; Shimamura M; Koriyama H; Nakagami F; Shimizu H; Miyake T; Yoshizumi M; Rakugi H; Morishita R
    Arterioscler Thromb Vasc Biol; 2013 Jun; 33(6):1287-96. PubMed ID: 23580147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RANKL links arterial calcification with osteolysis.
    Alexander MY
    Circ Res; 2009 May; 104(9):1032-4. PubMed ID: 19423860
    [No Abstract]   [Full Text] [Related]  

  • 14. Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-kappaB ligand in Mönckeberg's sclerosis and atherosclerosis.
    Schoppet M; Al-Fakhri N; Franke FE; Katz N; Barth PJ; Maisch B; Preissner KT; Hofbauer LC
    J Clin Endocrinol Metab; 2004 Aug; 89(8):4104-12. PubMed ID: 15292354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of Osteoprotegerin in Vascular Calcification and Bone Metabolism: The Basis for Developing New Therapeutics.
    Rochette L; Meloux A; Rigal E; Zeller M; Malka G; Cottin Y; Vergely C
    Calcif Tissue Int; 2019 Sep; 105(3):239-251. PubMed ID: 31197415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease.
    Kiechl S; Werner P; Knoflach M; Furtner M; Willeit J; Schett G
    Expert Rev Cardiovasc Ther; 2006 Nov; 4(6):801-11. PubMed ID: 17173497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TRAIL-deficiency accelerates vascular calcification in atherosclerosis via modulation of RANKL.
    Di Bartolo BA; Cartland SP; Harith HH; Bobryshev YV; Schoppet M; Kavurma MM
    PLoS One; 2013; 8(9):e74211. PubMed ID: 24040204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteoclast-Mediated Cell Therapy as an Attempt to Treat Elastin Specific Vascular Calcification.
    Simpson CL; Mosier JA; Vyavahare NR
    Molecules; 2021 Jun; 26(12):. PubMed ID: 34203711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular calcification and hypertension: cause and effect.
    Kalra SS; Shanahan CM
    Ann Med; 2012 Jun; 44 Suppl 1():S85-92. PubMed ID: 22713153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Updates on the Mechanisms and the Care of Cardiovascular Calcification in Chronic Kidney Disease.
    Hénaut L; Chillon JM; Kamel S; Massy ZA
    Semin Nephrol; 2018 May; 38(3):233-250. PubMed ID: 29753400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.